# primary IgAN FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/primary-igan

> No upcoming FDA catalysts in primary IgAN; 2 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2024 | [FILSPARI (sparsentan) FDA approval](https://sec-api.dev/pdufa/sparsentan) | TVTX | primary IgAN | completed, approved | "Our ability to generate significant product revenues and to achieve commercial success in the near-term will depend almost entirely on our ability to successfully commercialize our products in the United States, including FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression, which was granted full approval by the FDA in September 2024, and FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis ("FSGS") without nephrotic syndrome, which was granted full (traditional) approval by the FDA in April 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/tvtx-20260930.htm)) |
| Jul 2026 | [TRUTAKNA (atacicept) FDA approval](https://sec-api.dev/pdufa/atacicept) | VERA | primary IgAN | completed, approved | "TRUTAKNA, our first approved product, received accelerated approval from the FDA in July 2026 to reduce proteinuria in adults with primary IgAN who are at risk for disease progression." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1831828/000119312526449826/vera-20260930.htm)) |

## Drugs

- [FILSPARI (sparsentan)](https://sec-api.dev/pdufa/sparsentan) (TVTX)
- [TRUTAKNA (atacicept)](https://sec-api.dev/pdufa/atacicept) (VERA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/primary-igan.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "primary IgAN FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/primary-igan

```bibtex
@misc{secapidev_indications_primary_igan_20261116,
  title        = {primary IgAN FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/primary-igan}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_primary_igan_20261116","title":"primary IgAN FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/primary-igan","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
